Searchable abstracts of presentations at key conferences in endocrinology

ea0090rc5.2 | Rapid Communications 5: Adrenal and Cardiovascular Endocrinology 1 | ECE2023

Analysis of germline mutations in patients with non-syndromic adrenocortical carcinoma

Terzolo Massimo , Grisanti Salvatore , Scatolini Maria , Tomaiuolo Pasquale , Grosso Enrico , Basile Vittoria , Cosentini Deborah , Puglisi Soraya , Lagana Marta , Perotti Paola , Rossini Elisa , Sigala Sandra , Volante Marco , Berruti Alfredo

Background: Adrenocortical carcinoma (ACC) is a rare cancer associated with hereditary syndromes in 10% of cases. However, data on germline variants (GVs) in adult patients with sporadic ACC are limited.Methods: We analyzed germline DNA from 150 adult patients with sporadic ACC sequentially referred to our centers between 1998-2019. We designed a custom panel of 17 genes potentially involved in the pathogenesis of ACC: AIP, APC, ARMC5, ARNT, BRCA1, BRCA2...

ea0093oc17 | Oral communication 3: Adrenal Tumors and Neuroendocrine Tumors | EYES2023

Preclinical and clinical evidence of progesterone/megestrol acetate activity in metastatic adrenocortical carcinoma

Tamburello Mariangela , Abate Andrea , Turla Antonella , Lagana Marta , Rossini Elisa , Hantel Constanze , Tiberio Guido Alberto Massimo , Cosentini Deborah , Grisanti Salvatore , Berruti Alfredo , Sigala Sandra

Background: Adrenocortical carcinoma (ACC) is a rare cancer for which available systemic treatments, mitotane ± etoposide, doxorubicin and cisplatin (EDP-M), have limited efficacy.Objectives: Here, we strengthen the effect of progesterone (Pg) on metastatic ACC cell lines, studying whether it could influence growth, invasiveness, and metastasis formation. Additionally, we investigate if the Pg analogue megestrol-acetate administered with EDP-M could...

ea0081oc2.6 | Oral Communications 2: Adrenal and Cardiovascular Endocrinology 1 | ECE2022

Activity of abiraterone acetate in the management of cushing syndrome associated to advanced adrenocortical carcinoma: results of the ABACUS trial

Puglisi Soraya , Cosentini Deborah , Grisanti Salvatore , Basile Vittoria , Lagana Marta , Ferarri VittorioDomenico , Abate Andrea , Calabrese Anna , Rossini Elisa , Perotti Paola , Saba Laura , Pia Anna , Sigala Sandra , Berruti Alfredo , Terzolo Massimo

Background: More than 50% of adrenocortical carcinomas (ACC) in adults are associated with cortisol excess that makes tumor management challenging and has a negative impact on patient outcome. Abiraterone acetate (AA) is an irreversible inhibitor of the 17α-hydroxylase/C17, 20-lyase (CYP17 enzyme) that is used in patients with prostate cancer, in whom it leads to suppression of cortisol and androgens. The aim of this study was to assess the activity of AA to control corti...